How much weight will I lose on Ozempic?
Clinical trial projections, personalized to you
Medical Disclaimer: This tool provides general educational estimates. Always consult your prescribing physician or healthcare provider before making medication changes or interpreting results from population-based models.
Frequently Asked Questions
In the STEP 1 clinical trial (N=1,961), participants taking semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo. At the standard Ozempic doses (0.5 mg and 1.0 mg), the SUSTAIN trials showed weight loss typically ranges from 5% to 10% of body weight over 6-12 months.
Most people start noticing weight loss within 4-6 weeks of starting treatment. The rate of loss is typically fastest between weeks 12 and 28 during dose escalation.
The STEP 4 trial showed participants who switched from semaglutide 2.4 mg to placebo regained approximately two-thirds of the weight they had lost over the following 48 weeks.
Yes. All STEP clinical trials combined semaglutide with a reduced-calorie diet (500 kcal/day deficit) and increased physical activity (150 minutes/week). Dietary changes amplify results substantially.
Yes. The projections are derived from the STEP and SUSTAIN clinical trial programs published in the New England Journal of Medicine and The Lancet.
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. Link
- Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP 2). Lancet. 2021;397(10278):971-984. Link
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425. Link
- Novo Nordisk. Ozempic (semaglutide) Prescribing Information. FDA.gov. Link
Methodology
This calculator projects weight loss using dose-specific percentage outcomes from published clinical trials. For the 2.4 mg dose, projections are based on the STEP 1 trial (14.9% average body weight loss at 68 weeks). For the 1.0 mg and 0.5 mg doses, projections use data from the SUSTAIN trial program (~8% and ~5% at 52 weeks respectively).
Weight loss is calculated as a percentage of starting body weight and scaled proportionally to the selected treatment duration. This tool provides estimates only and does not replace clinical guidance.
Ozempic (semaglutide) is a GLP-1 receptor agonist. In the STEP 1 clinical trial, the 2.4 mg weekly dose produced 14.9% average body weight loss over 68 weeks. The standard Ozempic doses (0.5 mg and 1.0 mg) produce approximately 5-8% weight loss over 52 weeks in the SUSTAIN trials.
What else do you want to know?
Ask Pulse anything.